|What I would hope to achieve as an Ordinary Council Member
My contribution will be focused in the following: Since big data is the new-how and the future for
diagnosis, prognosis and treatment in CKD I would focus on a European Collaboration to implement big data in clinical nephrology practice. Nephrology is an amazing and complete specialty that should be recognized and well known, thus an effort should be made for having the same research fundings as other fields such cancer. In addition, we should improve our ability to attract talented and brilliant young investigators in the nephrology clinical and research basic field that includes kidney physiology, CKD, AKI, dialysis and kidney transplant.
|Full Name||Dr Maria Jose Soler Romeo|
|Education||University of Barcelona:M.D.1990-1996. MEDICINE. Hospital del Mar. Nephrology Fellow.
1998-2002. University of Catalonia: Master. 2003. KIDNEY TRANSPLANT Northwestern University
(Research Fellow). Division of Nephrology/Hypertension. Northwestern University Feinberg School of Medicine and Northwestern Memorial Hospital. Chicago, Illinois Nephrology/Diabetic
Nephropathy(2005-2006). PhD 2007.INTERNAL MEDICINE, NEPHROLOGY. (“Cum Laude”.
|Career||Attendant Nephrologist at the Nephrology Department at Hospital del Mar and an active role as a
clinical researcher within the Experimental Nephrologist Group. I have been involved as a PI in
several past and ongoing projects. I am associate professor Pompeu Fabra Univeristy, Barcelona,
Spain. My research in DKD has been consecutively funded by Instituto de Salud Carlos III(ISCIII) of the Spanish Government. I directed 4 doctoral thesis and currently directing 2 PhD students. I mentored more than 7 undergraduate students. I participated in the development of the “Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min)” from ERBP Workgroup Diabetes.
|Accomplishments||2017-Coordinator WP3. REDINREN Scientific committee: Generic Call 2017, Agence Nationale de
la Recherche 2017. Research Grant System, United Arab Emirates University 2017. Instituto Carlos III, FIS 2011/2016. XXXIII/XXVI Reunió Anual de la Societat Catalana de Nefrologia, Research Grant Manegement system, Diabetes UK 2017. Editorial Board: CKJ, BMC Nephrology.
|Publications (peer reviewed publications, first or senior author)
- 5 most important
|ACE2 inhibition worsens glomerular injury in association with increased ACE expression in
streptozotocin-induced diabetic mice. KIDNEY INTERNATIONAL2007. Localization of ACE2 in the
renal vasculature:amplification by angiotensin II type 1 receptor blockade using telmisartan. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY2009. Recurrence of IgA nephropathy and Henoch-Schonlein purpura after kidney transplantation: Risk factors and graft survival. TRANSPLANTATION PROCEEDINGS2005. Circulating endothelial progenitor cells after kidney transplantationl AJT2005.Role of Circulating Angiotensin Converting Enzyme 2 in Left Ventricular Remodeling following Myocardial Infarction: A Prospective Controlled Study PLOS ONE2013.
|Awards||Best Posters: Reunió Anual Societat Catalana de Nefrologia XX/XIV. Best Papers: Sociedad
Catalana de Nefrología 2005/2013. Best Abstracts: ERA-EDTA 45th, 48th, 52th. Reunión de
investigación en fisiopatología vascular de la SEH.LELHA 9ª/10ª.
|Contributions to the ERA-EDTA
and/or to national/ international nephrology
|Member:Sociedad Catalana de Nefrología, Fundació Catalana de Trasplantament, Sociedad
Española de Nefrología, ASN, ERA-EDTA, EDNSG, European Association for the Study of Diabetes,
REDINREN(Red de Investigación Renal), Advisory Board, ERBP Workgroup Diabetes, ERA-EDTA
wordking group: CKD-MBD, DESCARTES, DIABESITY. Active contributor to Spanish Society of
Nephrology working groups on diabetes (GEENDIAB) and glomerular disease.(GLOSEN).
How would you rate this page? (from 1 to 5, being 5 the best score)
Comment sent. Thank you for your cooperation.